Nivolumab Evidence: Trial Results and Peer-Reviewed Publications

Carcinoma, Non-Small-Cell Lung (207)

• Perioperative Nivolumab in Resectable Non-Small Cell Lung Cancer: A Subanalysis of Japanese Patients From CheckMate 77T.
  Cancer Sci · 2026 · PMID 41431434 · NCT04025879
• Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer.
  Clin Cancer Res · 2026 · PMID 41805895 · NCT03838159
• Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.
  Nat Cancer · 2026 · PMID 41507539 · NCT04025879
• The role of the molecular tumor board: learnings from the ROME trial.
  NPJ Precis Oncol · 2026 · PMID 41963505 · NCT04591431
• Updates on the Perioperative Management of Resectable Non-Small Cell Lung Cancer.
  J Natl Compr Canc Netw · 2026 · PMID 41911908 · NCT02595944

Neoplasms (199)

• Prospective evaluation of genomics-guided off-label treatment.
  Nature · 2026 · PMID 41986720 · NCT02925234
• First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.
  Nat Med · 2026 · PMID 41840238 · NCT03505320
• Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab.
  Clin Cancer Res · 2026 · PMID 41543348 · NCT03792724
• Phase I/II Study of the CDK2/9 Inhibitor Fadraciclib in Combination with Chemotherapy in Children with Advanced Malignancies: Arm K of the AcSé-ESMART Trial.
  Target Oncol · 2026 · PMID 41838385 · NCT02813135
• Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
  JCO Precis Oncol · 2026 · PMID 42018965 · NCT02693535

Melanoma (199)

• First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies.
  Target Oncol · 2026 · PMID 41824279 · NCT02702492
• A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors.
  Invest New Drugs · 2026 · PMID 41979863 · NCT05423262
• Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.
  Nat Med · 2026 · PMID 41606118 · NCT02977052
• Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial.
  J Immunother Precis Oncol · 2026 · PMID 39816915 · NCT02419495
• Immunological phenotype as a predictor for response after isolated limb perfusion for patients with melanoma in-transit metastasis.
  Eur J Surg Oncol · 2026 · PMID 41616426 · NCT03685890

Carcinoma, Renal Cell (98)

• Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma.
  J Immunother Cancer · 2026 · PMID 41617395 · NCT03141177
• Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent Therapy.
  Oncol Ther · 2026 · PMID 41239083 · NCT03141177
• A prospective external validation of the GRade, Age, Nodes and Tumor score in the ECOG-ACRIN EA8143 PROSPER trial.
  Oncologist · 2026 · PMID 41693026 · NCT03055013
• Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.
  Ann Oncol · 2025 · PMID 40180121 · NCT03075423
• Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial.
  Nat Commun · 2025 · PMID 39794332 · NCT04518046

Neoplasm Metastasis (66)

• Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial.
  Lancet Oncol · 2026 · PMID 41785896 · NCT04283890
• Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications.
  Semin Cancer Biol · 2025 · PMID 39863139 · NCT03878524
• CfDNA-based copy-number dynamics during anti-PD1 treatment in metastatic triple negative breast cancer.
  Cell Rep Med · 2025 · PMID 41406937 · NCT02499367
• NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08).
  BMJ Oncol · 2025 · PMID 39886516 · NCT03132038
• Inhibition of Bruton's tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors.
  JCI Insight · 2024 · PMID 39513363 · NCT03525925

Colorectal Neoplasms (60)

• Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer.
  J Immunother Cancer · 2026 · PMID 41571299 · NCT03184870
• Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial.
  Nat Commun · 2026 · PMID 41667470 · NCT04117087
• Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer.
  Nat Commun · 2026 · PMID 42034603 · NCT03832621
• Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1.
  J Immunother Cancer · 2025 · PMID 41407398 · NCT03981146
• Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.
  Lancet · 2025 · PMID 39874977 · NCT04008030

2026 (59 papers)

1. A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer).
   Yau T, Galle PR, Decaens T, et al. · Future Oncol · 2026 · Derived
   PubMed: PMID 41981891 · NCT04039607 (CheckMate 9DW) · Carcinoma, Hepatocellular
2. A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma.
   Wen PY, Manzanera A, Duault C, et al. · Neuro Oncol · 2026 · Derived
   PubMed: PMID 40120123 · NCT03576612 (GMCI) · Glioblastoma
3. Intraperitoneal nivolumab for malignant ascites in patients with advanced gastrointestinal or pancreaticobiliary tract cancer.
   Wang HT, Yu YL, Lo WJ, et al. · Int J Clin Oncol · 2026 · Derived
   PubMed: PMID 41369826 · NCT05745233
4. Current Status of Research on Losartan in Tumour Therapy.
   Wang H, Yuan S, Wang H, et al. · J Cell Mol Med · 2026 · Derived
   PubMed: PMID 41486497 · NCT03563248 · Pancreatic Neoplasms
5. Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.
   Walter TP, Mazieres J, Otto J, et al. · J Clin Oncol · 2026 · Derived
   PubMed: PMID 41774886 · NCT03591731 (NIPINEC) · Carcinoma, Neuroendocrine
6. Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma.
   Viray H, M Mantia C, Jegede OA, et al. · J Immunother Cancer · 2026 · Derived
   PubMed: PMID 41617395 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
7. Prospective evaluation of genomics-guided off-label treatment.
   Verkerk K, Spiekman AC, Haj Mohammad SF, et al. · Nature · 2026 · Derived
   PubMed: PMID 41986720 · NCT02925234 (DRUP) · Neoplasms
8. Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial.
   van den Hoek L, Burgmans M, Tong T, et al. · Lancet Oncol · 2026 · Derived
   PubMed: PMID 41785896 · NCT04283890 (CHOPIN) · Neoplasm Metastasis
9. Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1.
   Tselikas L, Susini S, Texier M, et al. · Nature · 2026 · Derived
   PubMed: PMID 42056527 · NCT02857569 (NIVIPIT)
10. Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial - BREASTIMMUNE-03.
    Trédan O, Loirat D, Chabaud S, et al. · Breast · 2026 · Derived
    PubMed: PMID 41314029 · NCT03818685 (BreastImmune03) · Breast Neoplasms
11. Perioperative Nivolumab in Resectable Non-Small Cell Lung Cancer: A Subanalysis of Japanese Patients From CheckMate 77T.
    Tanaka F, Watanabe Y, Sugawara S, et al. · Cancer Sci · 2026 · Derived
    PubMed: PMID 41431434 · NCT04025879 · Carcinoma, Non-Small-Cell Lung
12. Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609).
    Swiecicki PL, Othus M, Patel SP, et al. · Cancer · 2026 · Derived
    PubMed: PMID 41892875 · NCT02834013 · Carcinoma, Transitional Cell
13. Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer.
    Sierra-Rodero B, Gil-González Á, Molina-Alejandre M, et al. · Clin Cancer Res · 2026 · Derived
    PubMed: PMID 41805895 · NCT03838159 (NADIMII) · Carcinoma, Non-Small-Cell Lung
14. First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.
    Shitara K, Shoji H, Fazio N, et al. · Nat Med · 2026 · Derived
    PubMed: PMID 41840238 · NCT03505320 (ILUSTRO) · Neoplasms
15. Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.
    Scherpereel A, Baas P, Nowak AK, et al. · J Clin Oncol · 2026 · Derived
    PubMed: PMID 41734361 · NCT02899299 (CheckMate743) · Mesothelioma
16. Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab.
    Sanmamed MF, de Andrea CE, Ruiz-Guillamon D, et al. · Clin Cancer Res · 2026 · Derived
    PubMed: PMID 41543348 · NCT03792724 (INTRUST) · Neoplasms
17. Phase I/II Study of the CDK2/9 Inhibitor Fadraciclib in Combination with Chemotherapy in Children with Advanced Malignancies: Arm K of the AcSé-ESMART Trial.
    Rubio-San-Simón A, Marshall LV, Karamouza E, et al. · Target Oncol · 2026 · Derived
    PubMed: PMID 41838385 · NCT02813135 (ESMART) · Neoplasms
18. Gonadal Function and Fertility after Hodgkin Lymphoma Treatment with Nivolumab-AVD in the Phase II GHSG NIVAHL Trial.
    Robertz AS, Bühnen I, Meissner J, et al. · Blood · 2026 · Derived
    PubMed: PMID 41926569 · NCT03004833 (NIVAHL)
19. First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies.
    Razak A, Mahipal A, Diamond JR, et al. · Target Oncol · 2026 · Derived
    PubMed: PMID 41824279 · NCT02702492 (PANAMA) · Melanoma
20. Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.
    Provencio M, Awad MM, Spicer JD, et al. · Nat Cancer · 2026 · Derived
    PubMed: PMID 41507539 · NCT04025879 · Carcinoma, Non-Small-Cell Lung
21. Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Pisick E, Rothe M, Garrett-Mayer E, et al. · JCO Precis Oncol · 2026 · Derived
    PubMed: PMID 42018965 · NCT02693535 (TAPUR) · Neoplasms
22. NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal.
    Morris VK, Ciombor KK, Xiao L, et al. · J Clin Oncol · 2026 · Derived
    PubMed: PMID 41499716 · NCT02314169 · Anus Neoplasms
23. Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial.
    Mirghani H, Aupérin A, Even C, et al. · J Clin Oncol · 2026 · Derived
    PubMed: PMID 41570275 · NCT03838263 (IMMUNEBOOST) · Oropharyngeal Neoplasms
24. Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial.
    Mellema JJ, Stockem CF, Herberts C, et al. · Nat Med · 2026 · Derived
    PubMed: PMID 41760951 · NCT05200988 (Indi-Blade) · Carcinoma, Transitional Cell
25. IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort.
    Martin-Broto J, Strauss SJ, Palmerini E, et al. · Cancer Commun (Lond) · 2026 · Derived
    PubMed: PMID 41836677 · NCT03277924 (ImmunoSarc) · Sarcoma
26. The role of the molecular tumor board: learnings from the ROME trial.
    Marchetti P, Curigliano G, Westphalen CB, et al. · NPJ Precis Oncol · 2026 · Derived
    PubMed: PMID 41963505 · NCT04591431 (ROME) · Carcinoma, Non-Small-Cell Lung
27. Phase 2 Study of Cabozantinib (XL184) with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas (ETCTN10315).
    Mandl A, Chen R, Das S, et al. · Oncologist · 2026 · Derived
    PubMed: PMID 41968073 · NCT04079712 · Small Cell Lung Carcinoma
28. First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial.
    Lorenzen S, Goetze TO, Thuss-Patience PC, et al. · Nat Commun · 2026 · Derived
    PubMed: PMID 41760643 · NCT03647969
29. Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: Long-term efficacy and biomarker exploration.
    Lin YJ, Ou DL, Su YY, et al. · J Hepatol · 2026 · Derived
    PubMed: PMID 40972843 · NCT03510871 · Carcinoma, Hepatocellular
30. Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer.
    Le DT, Folprecht G, Varghese AM, et al. · J Immunother Cancer · 2026 · Derived
    PubMed: PMID 41571299 · NCT03184870 · Colorectal Neoplasms
31. A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors.
    Koyama T, Yonemori K, Sato J, et al. · Invest New Drugs · 2026 · Derived
    PubMed: PMID 41979863 · NCT05423262 · Melanoma
32. Phase II trial with nivolumab and sorafenib in HCC identified enrichment of immunosuppressive monocytes in patients with Child-Pugh B liver dysfunction.
    Keenan BP, Fan Z, Le BK, et al. · JHEP Rep · 2026 · Derived
    PubMed: PMID 41831609 · NCT03439891 · Carcinoma, Hepatocellular
33. Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial.
    Jones RL, Groisberg R, Blay JY, et al. · Nat Commun · 2026 · Derived
    PubMed: PMID 41611702 · NCT03684811 · Carcinoma, Hepatocellular
34. Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy.
    Johansen AZ, Novitski SI, Hjaltelin JX, et al. · Front Immunol · 2026 · Derived
    PubMed: PMID 37744345 · NCT02866383 (CheckPAC) · Pancreatic Neoplasms
35. Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer.
    Jarrard D, Eickhoff J, Kyriakopoulos CE, et al. · J Immunother Cancer · 2026 · Derived
    PubMed: PMID 41781018 · NCT04989946 · Prostatic Neoplasms
36. Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial.
    Huff AL, Haldar SD, Girgis AA, et al. · Nat Commun · 2026 · Derived
    PubMed: PMID 41667470 · NCT04117087 · Colorectal Neoplasms
37. Neoadjuvant immunochemoradiotherapy with nivolumab, paclitaxel, and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma.
    Huang TC, Guo JC, Lin CC, et al. · Br J Cancer · 2026 · Derived
    PubMed: PMID 41862680 · NCT05130684 (Neo-NTP-CRT)
38. Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.
    Hoeijmakers LL, Dimitriadis P, Wijnen SCMA, et al. · Nat Med · 2026 · Derived
    PubMed: PMID 41606118 · NCT02977052 (OpACIN-neo) · Melanoma
39. Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent Therapy.
    Grimm MO, Karim E, Kapetanakis V, et al. · Oncol Ther · 2026 · Derived
    PubMed: PMID 41239083 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
40. Checkpoint immunotherapy is associated with preferential activation of tumor antigen-specific CD4+ T cells in MDS.
    Griffiths EA, Srivastava P, Gomez EC, et al. · Blood Neoplasia · 2026 · Derived
    PubMed: PMID 40809194 · NCT03358719 · Leukemia, Myeloid, Acute
41. Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial.
    Gouda MA, Zarifa A, Yang Y, et al. · J Immunother Precis Oncol · 2026 · Derived
    PubMed: PMID 39816915 · NCT02419495 · Melanoma
42. Updates on the Perioperative Management of Resectable Non-Small Cell Lung Cancer.
    Frumm SM, Florez N, Lee JM, et al. · J Natl Compr Canc Netw · 2026 · Derived
    PubMed: PMID 41911908 · NCT02595944 (ANVIL) · Carcinoma, Non-Small-Cell Lung
43. A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma.
    Diefenbach CS, Jegede O, Wang V, et al. · Blood · 2026 · Derived
    PubMed: PMID 41662628 · NCT01896999
44. Immunological phenotype as a predictor for response after isolated limb perfusion for patients with melanoma in-transit metastasis.
    Constantinescu A, Olofsson Bagge R, Huibers A, et al. · Eur J Surg Oncol · 2026 · Derived
    PubMed: PMID 41616426 · NCT03685890 (NivoILP) · Melanoma
45. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Cobain EF, Rothe M, Garrett-Mayer E, et al. · JCO Precis Oncol · 2026 · Derived
    PubMed: PMID 42060861 · NCT02693535 (TAPUR) · Neoplasms
46. Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer.
    Choo J, Zhao JJ, Lau MC, et al. · Nat Commun · 2026 · Derived
    PubMed: PMID 42034603 · NCT03832621 (MAYA) · Colorectal Neoplasms
47. DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix.
    Chae YK, Othus M, Patel SP, et al. · J Immunother Cancer · 2026 · Derived
    PubMed: PMID 41672597 · NCT02834013 · Carcinoma, Transitional Cell
48. A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results.
    Chae YK, Czeskleba J, Patel SP, et al. · J Gynecol Oncol · 2026 · Derived
    PubMed: PMID 41995270 · NCT02834013 · Carcinoma, Transitional Cell
49. Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.
    Castellino SM, Li H, Herrera AF, et al. · J Clin Oncol · 2026 · Derived
    PubMed: PMID 41512237 · NCT03907488 · Hodgkin Disease
50. Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Carrizosa DR, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2026 · Derived
    PubMed: PMID 41538762 · NCT02693535 (TAPUR) · Neoplasms
51. Nivolumab and Ipilimumab in Advanced Mismatch Repair-Deficient/Microsatellite Instability-High Noncolorectal Cancers: A Nonrandomized Clinical Trial.
    Carlino MS, Gao B, Michael M, et al. · JAMA Oncol · 2026 · Derived
    PubMed: PMID 41231502 · NCT04969887 (MOST-CIRCUIT) · Neuroendocrine Tumors
52. A prospective external validation of the GRade, Age, Nodes and Tumor score in the ECOG-ACRIN EA8143 PROSPER trial.
    Buti S, Kim SE, Maffezzoli M, et al. · Oncologist · 2026 · Derived
    PubMed: PMID 41693026 · NCT03055013 · Carcinoma, Renal Cell
53. Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial.
    Bourhis J, Aupérin A, Borel C, et al. · Lancet · 2026 · Derived
    PubMed: PMID 41448222 · NCT03576417 (NIVOPOSTOP) · Squamous Cell Carcinoma of Head and Neck
54. PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials.
    Booth A, Hillman S, Laumann K, et al. · J Thorac Oncol · 2026 · Derived
    PubMed: PMID 41747891 · NCT06632327 · Lung Neoplasms
55. Next-Generation Immune Checkpoints and Tumor Microenvironment Modulation in Cancer Immunotherapy.
    Bautista J, Echeverría CE, Maldonado-Noboa I, et al. · J Immunol Res · 2026 · Derived
    PubMed: PMID 41811823 · NCT02983045 (PIVOT-02) · Melanoma
56. High dose interleukin-2 in combination with anti-programmed cell death protein 1 to overcome immune checkpoint inhibitor resistance in metastatic melanoma and renal cell carcinoma.
    Azenkot T, Nikanjam M, Mhatre S, et al. · Melanoma Res · 2026 · Derived
    PubMed: PMID 42070986 · NCT03991130 · Melanoma
57. Nivolumab for Resected Stage III or IV Melanoma at 9 Years.
    Ascierto PA, Del Vecchio M, Merelli B, et al. · N Engl J Med · 2026 · Derived
    PubMed: PMID 41124198 · NCT02388906 (CheckMate 238) · Melanoma
58. Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma.
    Abramson JS, Straus DJ, Bartlett NL, et al. · Blood · 2026 · Derived
    PubMed: PMID 41460964 · NCT03646123 · Hodgkin Disease
59. Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial.
    Zhu HD, Fan WJ, Zhao C, et al. · J Clin Oncol · 2026 · Background
    PubMed: PMID 41734362 · NCT07482059

2025 (113 papers)

1. Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1.
   Middleton G, Gaskell C, Savage J, et al. · J Immunother Cancer · 2025 · Trial result
   PubMed: PMID 41407398 · NCT03981146 (ANICCA) · Colorectal Neoplasms
2. Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial.
   Li R, Villa NY, Yu X, et al. · Nat Med · 2025 · Trial result
   PubMed: PMID 39521884 · NCT04610671 · Urinary Bladder Neoplasms
3. Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial.
   Dawson LA, Winter KA, Knox JJ, et al. · JAMA Oncol · 2025 · Trial result
   PubMed: PMID 39699905 · NCT07075120 · Carcinoma, Hepatocellular
4. Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.
   Bergmann L, Albiges L, Ahrens M, et al. · Ann Oncol · 2025 · Trial result
   PubMed: PMID 40180121 · NCT03075423 · Carcinoma, Renal Cell
5. Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma.
   Yu J, Mehta R · J Natl Compr Canc Netw · 2025 · Derived
   PubMed: PMID 40341124 · NCT03505320 (ILUSTRO) · Neoplasms
6. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.
   Yau T, Galle PR, Decaens T, et al. · Lancet · 2025 · Derived
   PubMed: PMID 40349714 · NCT04039607 (CheckMate 9DW) · Carcinoma, Hepatocellular
7. YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial.
   Yap TA, Kwiatkowski DJ, Dagogo-Jack I, et al. · Nat Med · 2025 · Derived
   PubMed: PMID 41111090 · NCT04665206 · Mesothelioma
8. Incorporating nivolumab with preceded gemcitabine and S-1 chemotherapy for patients of metastatic pancreatic cancer: a pilot study.
   Yang SH, Chen BB, Lee JC, et al. · Am J Cancer Res · 2025 · Derived
   PubMed: PMID 41113977 · NCT04377048 · Pancreatic Neoplasms
9. RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).
   Wong MK, Milhem MM, Sacco JJ, et al. · J Clin Oncol · 2025 · Derived
   PubMed: PMID 40627813 · NCT03767348 (IGNYTE) · Melanoma
10. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
    Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 39282897 · NCT01844505 · Melanoma
11. Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial.
    Wermke M, Araujo DM, Chatterjee M, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 40205198 · NCT03686124 (ACTengine) · Melanoma
12. Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials.
    Weber JS, Middleton MR, Yates G, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 39378385 · NCT02388906 (CheckMate 238) · Melanoma
13. Population Pharmacokinetics and Exposure-Response Analysis of Serplulimab in Small Cell Lung Cancer Patients.
    Wang K, Shen Y, Hu C, et al. · Clin Transl Sci · 2025 · Derived
    PubMed: PMID 40932107 · NCT04778904 · Hepatitis B
14. Newly diagnosed glioblastoma IDHwt patients treated with radiation, nivolumab, and BMS-986205.
    Wainwright D, Lukas R, Zhai L, et al. · Res Sq · 2025 · Derived
    PubMed: PMID 41041559 · NCT04047706 · Glioblastoma
15. Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.
    Tsao AS, Song Z, Ho AL, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 41066729 · NCT02465060 · Melanoma
16. Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications.
    Tost J, Ak-Aksoy S, Campa D, et al. · Semin Cancer Biol · 2025 · Derived
    PubMed: PMID 39863139 · NCT03878524 · Neoplasm Metastasis
17. Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.
    Torka P, Feldman T, Savage KJ, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 39661923 · NCT03033914 · Hodgkin Disease
18. Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunotherapy, chemotherapy, or chemoimmunotherapy.
    Toney NJ, Lynch MT, Lynce F, et al. · J Immunother Cancer · 2025 · Derived
    PubMed: PMID 40274284 · NCT03487666 · Triple Negative Breast Neoplasms
19. Nivolumab plus gemcitabine-cisplatin for previously untreated unresectable or metastatic urothelial carcinoma: an Asian subgroup analysis from the global phase 3 CheckMate 901 trial.
    Tomita Y, Ye DW, Fujii A, et al. · Urol Oncol · 2025 · Derived
    PubMed: PMID 41015742 · NCT03036098 (CheckMate901)
20. Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine.
    Thunold S, Hernes E, Farooqi S, et al. · Eur J Nucl Med Mol Imaging · 2025 · Derived
    PubMed: PMID 39133306 · NCT04300244 (NIPU) · Neoplasms
21. Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.
    Tawbi HA, Hodi FS, Lipson EJ, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 39671533 · NCT03470922 (RELATIVITY-047) · Melanoma
22. Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers.
    Tan PB, Verschoor YL, van den Berg JG, et al. · Nature · 2025 · Derived
    PubMed: PMID 41115454 · NCT03026140 (NICHE) · Colonic Neoplasms
23. Final clinical analysis of pre-operative ipilimumab and nivolumab in locally advanced urothelial cancer and exploration of tumor-draining lymph node composition: The NABUCCO trial.
    Stockem CF, van Dorp J, van Dijk N, et al. · Eur J Cancer · 2025 · Derived
    PubMed: PMID 40934711 · NCT03387761 (NABUCCO) · Neoplasms
24. Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas.
    Sarathkumara YD, Van Bibber NW, Liu Z, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 39908567 · NCT02973113 (PREVALE) · Hodgkin Disease
25. BilT03: Phase 1b/2 multicenter trial of nivolumab with 5-fluorouracil and liposomal irinotecan for previously treated advanced biliary tract cancer.
    Sahai V, Griffith KA, Lin BS, et al. · Med · 2025 · Derived
    PubMed: PMID 39701097 · NCT03785873 · Biliary Tract Neoplasms
26. S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE).
    Saeed A, Colby S, Oberstein PE, et al. · Future Oncol · 2025 · Derived
    PubMed: PMID 40155326 · NCT06203600 · Adenocarcinoma Of Esophagus
27. Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial.
    Rosenberg AJ, Juloori A, Jelinek MJ, et al. · JAMA Oncol · 2025 · Derived
    PubMed: PMID 40048190 · NCT03944915 (DEPEND) · Squamous Cell Carcinoma of Head and Neck
28. Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study.
    Robert C, Kicinski M, Dutriaux C, et al. · Lancet Oncol · 2025 · Derived
    PubMed: PMID 40449497 · NCT03235245 (EBIN) · Melanoma
29. Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses.
    Reuss JE, Lee PK, Mehran RJ, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 40921804 · NCT03918252 · Mesothelioma
30. Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047.
    Regan MM, Ascierto PA, Lipson EJ, et al. · J Immunother Cancer · 2025 · Derived
    PubMed: PMID 40940136 · NCT03470922 (RELATIVITY-047) · Melanoma
31. NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies.
    R Choo J, Jeraj SN, Sundar R, et al. · Ther Adv Med Oncol · 2025 · Derived
    PubMed: PMID 40502306 · NCT04850755
32. Consolidative nivolumab versus observation in unresectable stage III non-small cell lung cancer patients following neoadjuvant nivolumab plus chemotherapy and concurrent chemoradiotherapy (CA209-7AL): a randomized clinical trial.
    Qiu B, Zhao Y, He W, et al. · Signal Transduct Target Ther · 2025 · Derived
    PubMed: PMID 41016926 · NCT04085250 · Carcinoma, Non-Small-Cell Lung
33. Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia.
    Pyzer AR, Dillon LW, Sharon E, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 39928953 · NCT02275533 · Leukemia, Myeloid, Acute
34. Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis.
    Peters S, Paz-Ares LG, Reck M, et al. · J Thorac Oncol · 2025 · Derived
    PubMed: PMID 39369790 · NCT03215706 (CheckMate 9LA) · Carcinoma, Non-Small-Cell Lung
35. Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort.
    Patel SP, Fisher J, Chae YK, et al. · J Immunother Cancer · 2025 · Derived
    PubMed: PMID 40588371 · NCT02834013 · Carcinoma, Transitional Cell
36. Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma.
    Patel SP, Cano-Linson E, Chae YK, et al. · NPJ Precis Oncol · 2025 · Derived
    PubMed: PMID 39856213 · NCT02834013 · Carcinoma, Transitional Cell
37. Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study.
    Pandit-Taskar N, Mauguen A, Frosina D, et al. · Melanoma Res · 2025 · Derived
    PubMed: PMID 40557547 · NCT03122522 · Melanoma
38. STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma.
    Pal SK, Powles T, Kanesvaran R, et al. · Future Oncol · 2025 · Derived
    PubMed: PMID 40008409 · NCT05678673 (STELLAR-304)
39. Nivolumab in combination with R-CHOP for treatment-naïve diffuse large B-cell lymphoma: an evaluation of safety and efficacy.
    Odetola O, Ma S, Winter J, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 40706069 · NCT03704714 · Lymphoma, B-Cell
40. Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.
    Nguyen MK, Jelinek M, Singh A, et al. · Oncologist · 2025 · Derived
    PubMed: PMID 41138165 · NCT04056910 · Glioma
41. Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.
    Nguyen MK, Jelinek M, Singh A, et al. · medRxiv · 2025 · Derived
    PubMed: PMID 40778139 · NCT04056910 · Glioma
42. Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors.
    Nelson BE, O'Brien S, Sheth RA, et al. · J Immunother Cancer · 2025 · Derived
    PubMed: PMID 39824531 · NCT03444753
43. Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial.
    Msaouel P, Yu K, Yuan Y, et al. · Nat Commun · 2025 · Derived
    PubMed: PMID 39794332 · NCT04518046 · Carcinoma, Renal Cell
44. Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial.
    Motzer RJ, Bex A, Russo P, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 39303200 · NCT03138512 (CheckMate 914) · Carcinoma, Renal Cell
45. Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800).
    Menzies AM, Salman P, Frontera OA, et al. · Cancer · 2025 · Derived
    PubMed: PMID 40614118 · NCT02905266 · Melanoma
46. Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS).
    Martin-Broto J, Diaz-Beveridge R, Moura D, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 39356980 · NCT03277924 (ImmunoSarc) · Sarcoma
47. Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial.
    Marchetti P, Curigliano G, Biffoni M, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 41023484 · NCT04591431 (ROME) · Carcinoma, Non-Small-Cell Lung
48. Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study.
    Mangat PK, Kirkwood MK, Hinshaw DC, et al. · NPJ Precis Oncol · 2025 · Derived
    PubMed: PMID 40610648 · NCT02693535 (TAPUR) · Neoplasms
49. Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial.
    Luke JJ, Bever K, Hodi FS, et al. · J Immunother Cancer · 2025 · Derived
    PubMed: PMID 40389374 · NCT03335540 (ADVISE)
50. Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915.
    Long GV, Tang H, Desai K, et al. · J Immunother Cancer · 2025 · Derived
    PubMed: PMID 40645660 · NCT03068455 (CheckMate 915) · Melanoma
51. Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma.
    Long GV, Shklovskaya E, Satgunaseelan L, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 40016450 · NCT06816927 (GIANT)
52. Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.
    Long GV, Nair N, Marbach D, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 40993242 · NCT05116202 · Melanoma
53. Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.
    Long GV, Larkin J, Schadendorf D, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 39504507 · NCT01721772 (CheckMate 066) · Melanoma
54. Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.
    Long GV, Garnett-Benson C, Dolfi S, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 41109920 · NCT05002569 (RELATIVITY-098) · Melanoma
55. Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study.
    Long GV, Atkinson V, Lo SN, et al. · Lancet Oncol · 2025 · Derived
    PubMed: PMID 39978375 · NCT02374242 (ABC) · Melanoma
56. Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study.
    Lonardi S, Ługowska I, O'Donnell A, et al. · J Immunother Cancer · 2025 · Derived
    PubMed: PMID 41052885 · NCT03656718 · Neoplasms by Site
57. Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.
    Loi S, Salgado R, Curigliano G, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 39838118 · NCT04109066 (CheckMate 7FL) · Neoplasms
58. Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update.
    Lipson EJ, Stephen Hodi F, Tawbi H, et al. · Eur J Cancer · 2025 · Derived
    PubMed: PMID 40513285 · NCT03470922 (RELATIVITY-047) · Melanoma
59. Q-TWiST analysis of first-line nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma from CheckMate 649: 4-year follow-up results.
    Lin D, Quan W, Garretson M, et al. · Gastric Cancer · 2025 · Derived
    PubMed: PMID 40632415 · NCT02872116 (CheckMate649) · Stomach Neoplasms
60. CfDNA-based copy-number dynamics during anti-PD1 treatment in metastatic triple negative breast cancer.
    Lin AY, Isaeva OI, Deger T, et al. · Cell Rep Med · 2025 · Derived
    PubMed: PMID 41406937 · NCT02499367 (TONIC) · Neoplasm Metastasis
61. Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.
    Léna H, Greillier L, Cropet C, et al. · Lancet Respir Med · 2025 · Derived
    PubMed: PMID 39486424 · NCT03351361 (eNERGY)
62. A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC).
    Lee YJ, Lee YY, Park JY, et al. · J Gynecol Oncol · 2025 · Derived
    PubMed: PMID 39530558 · NCT05795244 · Endometrial Neoplasms
63. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma.
    Lee HJ, Ramchandren R, Friedman J, et al. · Blood · 2025 · Derived
    PubMed: PMID 39622165 · NCT03646123 · Hodgkin Disease
64. Programmed death-1 inhibition increases vaccine-induced T-cell infiltration in patients with prostate cancer.
    Lassoued W, Madan RA, Xue E, et al. · J Immunother Cancer · 2025 · Derived
    PubMed: PMID 40550568 · NCT02933255 · Prostatic Neoplasms
65. Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial.
    Lassman AB, Polley MC, Iwamoto FM, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 40779733 · NCT04396860 · Gliosarcoma
66. Dual Immune Checkpoint Inhibition Plus Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Randomized Clinical Trial.
    Laengle J, Kuehrer I, Kulu A, et al. · JAMA Netw Open · 2025 · Derived
    PubMed: PMID 40844778 · NCT04124601 (CHINOREC) · Rectal Neoplasms
67. Positron emission tomography-adapted therapy for first-line treatment in adults with Hodgkin lymphoma.
    Kreuzberger N, Goldkuhle M, von Tresckow B, et al. · Cochrane Database Syst Rev · 2025 · Derived
    PubMed: PMID 40135712 · NCT04866654 (RAFTING) · Hodgkin Disease
68. Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer.
    Konda B, Sherman EJ, Massarelli E, et al. · J Clin Endocrinol Metab · 2025 · Derived
    PubMed: PMID 39133806 · NCT03914300 · Thyroid Neoplasms
69. Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial.
    Kirkwood JM, Mohr P, Hoeller C, et al. · Eur J Cancer · 2025 · Derived
    PubMed: PMID 40139004 · NCT04099251 (CheckMate76K) · Melanoma
70. Phase I study on neoadjuvant combination immunotherapy with mogamulizumab and nivolumab for solid tumors.
    Jinushi K, Saito T, Kurose K, et al. · J Immunother Cancer · 2025 · Derived
    PubMed: PMID 40180420 · NCT02946671 · Lung Neoplasms
71. Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring.
    Jiao H, Lin S, Gu J, et al. · Mol Cancer · 2025 · Derived
    PubMed: PMID 40375301 · NCT05213312 · Esophageal Squamous Cell Carcinoma
72. PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
    Janku F, Jegede OA, Puhalla SL, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 40865033 · NCT02465060 · Melanoma
73. Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204.
    Huang RY, Youssef G, Nelson T, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 39752606 · NCT02320058 (CheckMate204) · Melanoma
74. A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCC.
    Hahn AW, Adra N, Vaishampayan U, et al. · Oncologist · 2025 · Derived
    PubMed: PMID 40212021 · NCT04904302 · Carcinoma, Renal Cell
75. 18F-BMS-986229 PET imaging of tumor PD-L1 expression in glioblastoma patients.
    Grkovski M, Daras M, Bale T, et al. · EJNMMI Res · 2025 · Derived
    PubMed: PMID 41003913 · NCT02617589 (CheckMate 498) · Brain Neoplasms
76. Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H.
    Gouda MA, Wei Z, Rodon J, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 39913886 · NCT02465060 · Melanoma
77. Neoadjuvant immunotherapy for muscle-invasive bladder cancer: a 2025 update.
    Giannakodimos I, Ziogou A, Giannakodimos A, et al. · Immunotherapy · 2025 · Derived
    PubMed: PMID 40329651 · NCT03520491 · Urinary Bladder Neoplasms
78. Estimating the Impact of Adjuvant Treatment With Nivolumab on Long-Term Survivorship Rates Compared With Surveillance in Muscle Invasive Urothelial Carcinoma: Mixture Cure Modeling Analyses of Disease-Free Survival From the Phase 3 CheckMate 274 Trial.
    Geynisman DM, Chepynoga K, Yates G, et al. · Clin Genitourin Cancer · 2025 · Derived
    PubMed: PMID 40204616 · NCT02632409 (CheckMate 274)
79. An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016.
    Gelsomino F, Boni L, Tiseo M, et al. · Lung Cancer · 2025 · Derived
    PubMed: PMID 39700681 · NCT03542461 (EDEN)
80. Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial.
    Gao B, Carlino MS, Michael M, et al. · JAMA Oncol · 2025 · Derived
    PubMed: PMID 40608313 · NCT04969887 (MOST-CIRCUIT) · Neuroendocrine Tumors
81. Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial.
    Galsky MD, Bajorin DF, Tomita Y, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 40775055 · NCT02632409 (CheckMate 274)
82. Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT).
    Galarza Fortuna GM, Grass D, Maughan BL, et al. · J Immunother Cancer · 2025 · Derived
    PubMed: PMID 40102029 · NCT03171025 (NEXT) · Urinary Bladder Neoplasms
83. Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.
    Forde PM, Spicer JD, Provencio M, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 40454642 · NCT02998528 (CheckMate 816) · Carcinoma, Non-Small-Cell Lung
84. Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.
    Fizazi K, Saad F, Alonso-Gordoa T, et al. · Lancet Oncol · 2025 · Derived
    PubMed: PMID 41449150 · NCT04100018 (CheckMate 7DX) · Prostatic Neoplasms
85. NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08).
    Fayette J, Even C, Digue L, et al. · BMJ Oncol · 2025 · Derived
    PubMed: PMID 39886516 · NCT03132038 (NISCAHN) · Neoplasm Metastasis
86. Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study.
    Depotte L, Nay P, Borg C, et al. · J Immunother Cancer · 2025 · Derived
    PubMed: PMID 40389373 · NCT03350126 (NIPICOL) · Colonic Neoplasms
87. Anti-PD-1 and anti-PD-L1 antibodies for glioma.
    de Melo SM, Elias Nunes da Silva ME, Torloni MR, et al. · Cochrane Database Syst Rev · 2025 · Derived
    PubMed: PMID 39777725 · NCT04195139 (NUTMEG) · Glioblastoma
88. Health-related quality of life in patients with unresectable hepatocellular carcinoma treated with SIRT and nivolumab: a sub-analysis of the NASIR-HCC trial.
    De la Torre-Aláez M, Matilla A, Varela M, et al. · J Patient Rep Outcomes · 2025 · Derived
    PubMed: PMID 40198533 · NCT03380130 (NASIR-HCC) · Carcinoma, Hepatocellular
89. Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults: A Nonrandomized Clinical Trial.
    Daw S, Cole PD, Hoppe BS, et al. · JAMA Oncol · 2025 · Derived
    PubMed: PMID 39745739 · NCT02927769 (CheckMate 744) · Hodgkin Disease
90. Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas.
    Chihara D, Steiner RE, Nair R, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 39908461 · NCT03770416
91. Circulating miRNAs as potentially predictive biomarkers for chemoimmunotherapy in advanced biliary tract cancer: a post-hoc analysis of the phase II T1219 study.
    Chiang NJ, Tang CY, Bai LY, et al. · NPJ Precis Oncol · 2025 · Derived
    PubMed: PMID 40885799 · NCT04172402
92. Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma).
    Chae YK, Othus M, Patel SP, et al. · Ther Adv Med Oncol · 2025 · Derived
    PubMed: PMID 39583952 · NCT02834013 · Carcinoma, Transitional Cell
93. Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma (ACC) of all Anatomic Sites of Origin and Other Malignant Salivary Gland Tumors.
    Chae YK, Duan R, Chung LI, et al. · Cancer Med · 2025 · Derived
    PubMed: PMID 40166913 · NCT03146650 · Salivary Gland Neoplasms
94. Plain language summary of quality of life in CheckMate 9ER: Cabozantinib plus nivolumab in advanced renal cell carcinoma.
    Cella D, Motzer RJ, Suarez C, et al. · Future Oncol · 2025 · Derived
    PubMed: PMID 39452894 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
95. MAPK Pathway-Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial.
    Cappuzzo F, Ricciuti B, Delmonte A, et al. · Clin Cancer Res · 2025 · Derived
    PubMed: PMID 39836372 · NCT03823625 (SQUINT)
96. Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.
    Burton EM, Milton DR, Tetzlaff MT, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 40638872 · NCT02519322 · Melanoma
97. Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.
    Breukers SE, Traets JJH, van Dijk SW, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 41062829 · NCT04620200 (MATISSE)
98. Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415).
    Bozorgmehr F, Chung I, Fischer JR, et al. · Clin Exp Metastasis · 2025 · Derived
    PubMed: PMID 40702361 · NCT03044626 (FORCE) · Carcinoma, Non-Small-Cell Lung
99. Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study.
    Bhatia S, Topalian SL, Sharfman W, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 39889250 · NCT02488759 (CheckMate358)
100. Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma.
     Beckermann KE, Shah NJ, Campbell MT, et al. · Oncologist · 2025 · Derived
     PubMed: PMID 40549043 · NCT04300140 · Carcinoma, Renal Cell
101. Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS).
     Barroso-Sousa R, Zanudo JGT, Li T, et al. · Nat Commun · 2025 · Derived
     PubMed: PMID 40360544 · NCT03789110 · Breast Neoplasms
102. A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial.
     Baretti M, Kirk AM, Ladle BH, et al. · Nat Med · 2025 · Derived
     PubMed: PMID 41286513 · NCT04248569 · Fibrolamellar hepatocellular carcinoma
103. Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.
     Awad MM, Forde PM, Girard N, et al. · J Clin Oncol · 2025 · Derived
     PubMed: PMID 39778121 · NCT02998528 (CheckMate 816) · Carcinoma, Non-Small-Cell Lung
104. Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020.
     Ascierto PA, Tang H, Dolfi S, et al. · J Immunother Cancer · 2025 · Derived
     PubMed: PMID 40010775 · NCT01968109 · Neoplasms by Site
105. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.
     André T, Elez E, Lenz HJ, et al. · Lancet · 2025 · Derived
     PubMed: PMID 39874977 · NCT04008030 (CheckMate 8HW) · Colorectal Neoplasms
106. A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma.
     Alhalabi O, Gouda MA, Milton DR, et al. · Cancer Med · 2025 · Derived
     PubMed: PMID 39945382 · NCT02419495 · Melanoma
107. Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
     Al Baghdadi T, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2025 · Derived
     PubMed: PMID 41100773 · NCT02693535 (TAPUR) · Neoplasms
108. Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib study.
     Ahmed KA, Kim Y, Kim S, et al. · J Immunother Cancer · 2025 · Derived
     PubMed: PMID 40295143 · NCT03807765 · Breast Neoplasms
109. State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now.
     Tripp MK, Watson M, Balk SJ, et al. · CA Cancer J Clin · 2025 · Background
     PubMed: PMID 27232110 · NCT03817125 (MCGRAW) · Melanoma
110. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
     Sangro B, Kudo M, Erinjeri JP, et al. · Lancet · 2025 · Background
     PubMed: PMID 39798579 · NCT07482059
111. Transarterial radioembolization versus chemoembolization for hepatocellular carcinoma: a meta-analysis.
     Lu W, Zhang T, Xia F, et al. · Front Oncol · 2025 · Background
     PubMed: PMID 39896190 · NCT07482059
112. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
     Kudo M, Ren Z, Guo Y, et al. · Lancet · 2025 · Background
     PubMed: PMID 39798578 · NCT07482059
113. Upfront Versus Deferred Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-analysis.
     Esagian SM, Karam JA, Msaouel P, et al. · Eur Urol Focus · 2025 · Background
     PubMed: PMID 39289076 · NCT07233668 (IVE in mRCC) · Carcinoma, Renal Cell

2024 (147 papers)

1. Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced Melanoma.
   Tarhini AA, Eroglu Z, Eljilany I, et al. · Clin Cancer Res · 2024 · Trial result
   PubMed: PMID 39417680 · NCT04526730 · Melanoma
2. Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial.
   Schuler M, Cuppens K, Plönes T, et al. · Nat Med · 2024 · Trial result
   PubMed: PMID 38689060 · NCT04205552 (NEOpredict) · Carcinoma, Non-Small-Cell Lung
3. REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas.
   Picca A, Touat M, Belin L, et al. · Eur J Cancer · 2024 · Trial result
   PubMed: PMID 38537315 · NCT03925246 (REVOLUMAB) · Brain Neoplasms
4. Synthetic retinoid-mediated preconditioning of cancer-associated fibroblasts and macrophages improves cancer response to immune checkpoint blockade.
   Owaki T, Iida T, Miyai Y, et al. · Br J Cancer · 2024 · Trial result
   PubMed: PMID 38849479 · NCT06983210 (GRAPE) · Carcinoma, Transitional Cell
5. The Yin and Yang of Cytoreductive SBRT in Oligometastases and Beyond.
   Onderdonk BE, Chmura SJ · Front Oncol · 2024 · Trial result
   PubMed: PMID 31428580 · NCT07075120 · Carcinoma, Hepatocellular
6. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
   Luke JJ, Rutkowski P, Queirolo P, et al. · Lancet · 2024 · Trial result
   PubMed: PMID 35367007 · NCT06488482
7. Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial.
   Li Z, Liu J, Zhang B, et al. · Nat Commun · 2024 · Trial result
   PubMed: PMID 38627377 · NCT07075120 · Carcinoma, Hepatocellular
8. Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis.
   Knisely A, Hinchcliff E, Fellman B, et al. · Med · 2024 · Trial result
   PubMed: PMID 38471508 · NCT03508570 · Ovarian Neoplasms
9. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN).
   Isfort S, von Bubnoff N, Al-Ali HK, et al. · Ann Hematol · 2024 · Trial result
   PubMed: PMID 38967662 · NCT05393674 · Primary Myelofibrosis
10. The effect of a single dose of nivolumab prior to isolated limb perfusion for patients with in-transit melanoma metastases: An interim analysis of a phase Ib/II randomized double-blind placebo-controlled trial (NivoILP trial).
    Holmberg CJ, Zijlker LP, Katsarelias D, et al. · Eur J Surg Oncol · 2024 · Trial result
    PubMed: PMID 38493679 · NCT03685890 (NivoILP) · Melanoma
11. PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy.
    Grivas P, Koshkin VS, Chu X, et al. · Eur Urol Oncol · 2024 · Trial result
    PubMed: PMID 38155060 · NCT03532451 (PrE0807) · Urinary Bladder Neoplasms
12. Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.
    Davar D, Morrison RM, Dzutsev AK, et al. · Cancer Cell · 2024 · Trial result
    PubMed: PMID 39486411 · NCT03618641 · Melanoma
13. Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients.
    Dalle S, Verronese E, N'Kodia A, et al. · Oncoimmunology · 2024 · Trial result
    PubMed: PMID 38939518 · NCT02626065 (PAIR) · Melanoma
14. Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.
    Boudadi K, Suzman DL, Anagnostou V, et al. · Oncotarget · 2024 · Trial result
    PubMed: PMID 29983880 · NCT02601014 (STARVE-PC) · Prostatic Neoplasms
15. Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial.
    Andresen NK, Røssevold AH, Quaghebeur C, et al. · J Immunother Cancer · 2024 · Trial result
    PubMed: PMID 38242720 · NCT03409198 (ICON) · Neoplasms
16. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.
    Abou-Alfa GK, Lau G, Kudo M, et al. · NEJM Evid · 2024 · Trial result
    PubMed: PMID 38319892 · NCT07075120 · Carcinoma, Hepatocellular
17. Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study.
    Zhang B, Liu H, Shi C, et al. · BMC Cancer · 2024 · Derived
    PubMed: PMID 38862908 · NCT04507906 · Carcinoma, Non-Small-Cell Lung
18. Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial.
    Wu J, Zhang S, Yu S, et al. · Nat Commun · 2024 · Derived
    PubMed: PMID 39406730 · NCT04503967 (OASIS) · Stomach Neoplasms
19. Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Worden FP, Pisick E, Rothe M, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 39413339 · NCT02693535 (TAPUR) · Neoplasms
20. Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.
    Weber J, Del Vecchio M, Mandalá M, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 39102624 · NCT02388906 (CheckMate 238) · Melanoma
21. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
    Wainberg ZA, Kang YK, Lee KW, et al. · Gastric Cancer · 2024 · Derived
    PubMed: PMID 38308771 · NCT05111626 (FORTITUDE-102) · Stomach Neoplasms
22. Stereotactic Radiotherapy Plus Nivolumab in Patients with Locally Advanced Pancreatic Cancer: Results from Phase 1/2 Clinical CA209-9KH Trial.
    Vošmik M, John S, Dvořák J, et al. · Oncol Ther · 2024 · Derived
    PubMed: PMID 39441483 · NCT04098432 (CA209-9KH) · Pancreatic Neoplasms
23. Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer.
    Tsukada Y, Bando H, Inamori K, et al. · Br J Cancer · 2024 · Derived
    PubMed: PMID 38834744 · NCT02948348 · Rectal Neoplasms
24. Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma.
    Tijtgat J, Geeraerts X, Boisson A, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 38212127 · NCT03707808 (myDAvIpNi)
25. Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09).
    Tannir NM, Formiga MN, Penkov K, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38838287 · NCT03729245 · Carcinoma, Renal Cell
26. Phase I PIANO trial-PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes.
    Sundar R, Chia DKA, Zhao JJ, et al. · ESMO Open · 2024 · Derived
    PubMed: PMID 39288528 · NCT03172416 (PIPAC) · Stomach Neoplasms
27. Revolutionizing cancer drug development: Harnessing the potential of basket trials.
    Subbiah V, Burris HA, Kurzrock R, et al. · Cancer · 2024 · Derived
    PubMed: PMID 37934000 · NCT02465060 · Melanoma
28. Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial.
    Stockem CF, Mellema JJJ, van Rhijn BWG, et al. · Front Oncol · 2024 · Derived
    PubMed: PMID 37711193 · NCT05200988 (Indi-Blade) · Carcinoma, Transitional Cell
29. Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Srkalovic G, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 38865672 · NCT02693535 (TAPUR) · Neoplasms
30. NRG-BN002: Phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastoma.
    Sloan AE, Winter K, Gilbert MR, et al. · Neuro Oncol · 2024 · Derived
    PubMed: PMID 38874333 · NCT02311920 · Gliosarcoma
31. A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses.
    Seligson ND, Chen JL, Goodrich AC, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 39343511 · NCT02500797 · Sarcoma
32. Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical Trial.
    Sehgal K, Pappa T, Shin KY, et al. · JAMA Oncol · 2024 · Derived
    PubMed: PMID 39446365 · NCT03246958 · Thyroid Neoplasms
33. Inhibition of Bruton's tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors.
    Schwarz E, Benner B, Wesolowski R, et al. · JCI Insight · 2024 · Derived
    PubMed: PMID 39513363 · NCT03525925 · Neoplasm Metastasis
34. Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Schuetze S, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 39013131 · NCT02693535 (TAPUR) · Neoplasms
35. Checkpoint inhibition for early-stage hormone receptor-positive breast cancer.
    Schlam I, Corti C, Sammons S, et al. · Expert Opin Biol Ther · 2024 · Derived
    PubMed: PMID 38913933 · NCT04109066 (CheckMate 7FL) · Neoplasms
36. Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.
    Schenker M, Burotto M, Richardet M, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 39107131 · NCT03668119 (CheckMate 848)
37. Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers.
    Schenk KM, Deutsch JS, Chandra S, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38252910 · NCT03816332 · Melanoma
38. Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial.
    Saba NF, Wong SJ, Nasti T, et al. · JAMA Oncol · 2024 · Derived
    PubMed: PMID 38780927 · NCT03521570 · Squamous Cell Carcinoma of Head and Neck
39. Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial.
    Rosenberg AJ, Agrawal N, Juloori A, et al. · JAMA Oncol · 2024 · Derived
    PubMed: PMID 38842838 · NCT03107182 (OPTIMA-II) · Squamous Cell Carcinoma of Head and Neck
40. Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy.
    Root JL, Desai PN, Ly C, et al. · Cancer Res Commun · 2024 · Derived
    PubMed: PMID 38391202 · NCT02397720 · Leukemia, Myeloid, Acute
41. Molecularly Defined Thoracic Neoplasms.
    Roden AC · Adv Anat Pathol · 2024 · Derived
    PubMed: PMID 38501690 · NCT05407441 · Sarcoma
42. First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial.
    Ree AH, Šaltytė Benth J, Hamre HM, et al. · Br J Cancer · 2024 · Derived
    PubMed: PMID 38664577 · NCT03388190 (METIMMOX) · Neoplasm Metastasis
43. Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade.
    Ree AH, Høye E, Esbensen Y, et al. · Oncoimmunology · 2024 · Derived
    PubMed: PMID 38952672 · NCT03388190 (METIMMOX) · Neoplasm Metastasis
44. Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial.
    Reck M, Ciuleanu TE, Schenker M, et al. · Eur J Cancer · 2024 · Derived
    PubMed: PMID 39270380 · NCT03215706 (CheckMate 9LA) · Carcinoma, Non-Small-Cell Lung
45. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results.
    Rappaport AR, Kyi C, Lane M, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 38538867 · NCT03953235 · Carcinoma, Non-Small-Cell Lung
46. Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma.
    Ramirez CA, Becker-Hapak M, Singhal K, et al. · Blood Adv · 2024 · Derived
    PubMed: PMID 38713894 · NCT03121677 · Lymphoma, Follicular
47. Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion-A Phase 2, Prospective Interventional Study.
    Ram R, Amit O, Perry C, et al. · Transplant Cell Ther · 2024 · Derived
    PubMed: PMID 39396632 · NCT05385263 · Lymphoma, B-Cell
48. Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study.
    Rajdev L, Jackie Wang CC, Joshi H, et al. · Cancer · 2024 · Derived
    PubMed: PMID 37962072 · NCT02408861 · Neoplasm Metastasis
49. Circulating cancer-specific CD8 T cell frequency is associated with response to PD-1 blockade in Merkel cell carcinoma.
    Pulliam T, Jani S, Jing L, et al. · Cell Rep Med · 2024 · Derived
    PubMed: PMID 38340723 · NCT02488759 (CheckMate358)
50. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial.
    Provencio M, Nadal E, Insa A, et al. · Lancet Oncol · 2024 · Derived
    PubMed: PMID 39419061 · NCT03081689 · Carcinoma, Non-Small-Cell Lung
51. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial.
    Powles T, Burotto M, Escudier B, et al. · ESMO Open · 2024 · Derived
    PubMed: PMID 38642472 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
52. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study.
    Perez JK, Kleber J, Rothe M, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 38564684 · NCT02693535 (TAPUR) · Neoplasms
53. Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort.
    Patel SP, Othus M, Chae YK, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 39067873 · NCT02834013 · Carcinoma, Transitional Cell
54. SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer.
    Patel SP, Guadarrama E, Chae YK, et al. · Cancer · 2024 · Derived
    PubMed: PMID 38358334 · NCT02834013 · Carcinoma, Transitional Cell
55. Localized FDG loss in lung cancer lesions.
    Parodi D, Dighero E, Biddau G, et al. · EJNMMI Res · 2024 · Derived
    PubMed: PMID 39485534 · NCT02475382 (CheckMate 169)
56. Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer.
    Park C, Suh KJ, Kim SH, et al. · Cancer Immunol Immunother · 2024 · Derived
    PubMed: PMID 39105849 · NCT04061863 (KORNELIA) · Breast Neoplasms
57. Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study.
    Overman MJ, Gelsomino F, Aglietta M, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 38821718 · NCT02060188 (CheckMate142)
58. Phase 1b/2 study of the liposomal formulation of eribulin (E7389-LF) in combination with nivolumab: Results from the phase 2 esophageal cancer cohort.
    Oshima T, Yamamoto S, Kawakami H, et al. · BJC Rep · 2024 · Derived
    PubMed: PMID 39516370 · NCT04078295 · Neoplasms
59. Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab.
    Ornstein MC, George L, Wei W, et al. · Clin Genitourin Cancer · 2024 · Derived
    PubMed: PMID 39208489 · NCT03126331 · Carcinoma, Renal Cell
60. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.
    Oaknin A, Moore K, Meyer T, et al. · Lancet Oncol · 2024 · Derived
    PubMed: PMID 38608691 · NCT02488759 (CheckMate358)
61. Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment.
    O'Connell BC, Hubbard C, Zizlsperger N, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 39214650 · NCT02637531 · Melanoma
62. Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.
    Nederlof I, Isaeva OI, de Graaf M, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 39284953 · NCT03815890 (BELLINI) · Breast Neoplasms
63. Distinct autoantibody profiles across checkpoint inhibitor types and toxicities.
    Mu-Mosley H, von Itzstein MS, Fattah F, et al. · Oncoimmunology · 2024 · Derived
    PubMed: PMID 38737792 · NCT01896999
64. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.
    Mok T, Nakagawa K, Park K, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38252907 · NCT02864251 (CheckMate722) · Carcinoma, Non-Small-Cell Lung
65. Combination of oligo-fractionated irradiation with nivolumab can induce immune modulation in gastric cancer.
    Mimura K, Ogata T, Nguyen PHD, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 38290769 · NCT03453164 · Stomach Neoplasms
66. First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer.
    Mercinelli C, Moschini M, Cigliola A, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 39241203 · NCT04876313 (NURE-Combo)
67. The Management of older patients with Hodgkin lymphoma: implications of S1826.
    McKenna M, Ryu Tiger YK, Rutherford SC, et al. · Semin Hematol · 2024 · Derived
    PubMed: PMID 38945791 · NCT03907488 · Hodgkin Disease
68. A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer.
    Mason M, Lapuente-Santana Ó, Halkola AS, et al. · J Transl Med · 2024 · Derived
    PubMed: PMID 38383458 · NCT02041533 · Carcinoma, Non-Small-Cell Lung
69. Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.
    Markowski MC, Taplin ME, Aggarwal R, et al. · Nat Commun · 2024 · Derived
    PubMed: PMID 38167882 · NCT03554317 (COMBAT-CRPC) · Prostatic Neoplasms
70. Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214.
    Mantia CM, Jegede OA, Plimack ER, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 39060019 · NCT02231749 · Carcinoma, Renal Cell
71. Phase I/II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): Big ten cancer research consortium (BTCRC-LUN17-127) study.
    Malhotra J, Chiappori A, Fujioka N, et al. · Lung Cancer · 2024 · Derived
    PubMed: PMID 39173229 · NCT03575793 · Lung Neoplasms
72. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma.
    Long GV, Stephen Hodi F, Lipson EJ, et al. · NEJM Evid · 2024 · Derived
    PubMed: PMID 38320023 · NCT03470922 (RELATIVITY-047) · Melanoma
73. Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA study.
    Li M, Meindl-Beinker NM, Maenz M, et al. · J Geriatr Oncol · 2024 · Derived
    PubMed: PMID 39097500 · NCT03416244 (RAMONA) · Esophageal Neoplasms
74. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial.
    Lenz HJ, Parikh A, Spigel DR, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 38485190 · NCT03414983 (CheckMate 9X8) · Colorectal Neoplasms
75. Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).
    Kim JW, Lee HJ, Lee JY, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 38485184 · NCT04761744 · Neoplasm Metastasis
76. Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial.
    Kim HD, Jung S, Lim HY, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 38374347 · NCT04310709 (RENOBATE) · Carcinoma, Hepatocellular
77. Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study.
    Kim BH, Park HC, Kim TH, et al. · JHEP Rep · 2024 · Derived
    PubMed: PMID 38463541 · NCT04611165 (Nextrah)
78. Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.
    Khushalani NI, Ott PA, Ferris RL, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 38458639 · NCT02253992
79. Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas.
    Kesari S, Wojcinski A, Pabla S, et al. · Oncoimmunology · 2024 · Derived
    PubMed: PMID 39572979 · NCT03425292
80. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses.
    Kelly RJ, Landon BV, Zaidi AH, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 38504015 · NCT03044613 · Stomach Neoplasms
81. Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort.
    Kawazoe A, Yamamoto N, Sugimoto N, et al. · Clin Cancer Res · 2024 · Derived
    PubMed: PMID 38295160 · NCT04078295 · Neoplasms
82. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
    Kang YK, Terashima M, Kim YW, et al. · Lancet Gastroenterol Hepatol · 2024 · Derived
    PubMed: PMID 38906161 · NCT03006705 · Stomach Neoplasms
83. A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.
    Juric D, Barve M, Vaishampayan U, et al. · Cancer Med · 2024 · Derived
    PubMed: PMID 38501219 · NCT02834247 · Carcinoma, Non-Small-Cell Lung
84. Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.
    Janssen JC, van Dijk B, de Joode K, et al. · BMC Cancer · 2024 · Derived
    PubMed: PMID 38783238 · NCT05652673 · Melanoma
85. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.
    Janjigian YY, Ajani JA, Moehler M, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38382001 · NCT02872116 (CheckMate649) · Stomach Neoplasms
86. Quality of life and patient-reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy.
    Hoogland AI, Brohl AS, Small BJ, et al. · Cancer Med · 2024 · Derived
    PubMed: PMID 39021272 · NCT03071406 · Neoplasm Metastasis
87. Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.
    Herrera AF, LeBlanc M, Castellino SM, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 39413375 · NCT03907488 · Hodgkin Disease
88. First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.
    Hegewisch-Becker S, Mendez G, Chao J, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38723227 · NCT03662659 · Stomach Neoplasms
89. Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer.
    Heath EI, Chen W, Choi JE, et al. · Invest New Drugs · 2024 · Derived
    PubMed: PMID 39503807 · NCT04159896 · Prostatic Neoplasms
90. Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial.
    Hanna GJ, Villa A, Nandi SP, et al. · JAMA Oncol · 2024 · Derived
    PubMed: PMID 37971722 · NCT03692325 · Leukoplakia, Oral
91. Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass).
    Grünwald V, Ivanyi P, Zschäbitz S, et al. · Eur Urol · 2024 · Derived
    PubMed: PMID 37758574 · NCT02959554 (NIVOSWITCH) · Carcinoma, Renal Cell
92. Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial.
    Grimm MO, Schostak M, Grün CB, et al. · JAMA Oncol · 2024 · Derived
    PubMed: PMID 38722641 · NCT03219775 (TITAN-TCC) · Neoplasm Metastasis
93. Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma.
    Gonzalez-Kozlova E, Huang HH, Jagede OA, et al. · Cancer Res Commun · 2024 · Derived
    PubMed: PMID 38934093 · NCT01896999
94. Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V.
    Gien LT, Song Z, Poklepovic A, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 39666929 · NCT02465060 · Melanoma
95. Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.
    Geurts BS, Zeverijn LJ, Leek LVM, et al. · Clin Cancer Res · 2024 · Derived
    PubMed: PMID 38630551 · NCT02925234 (DRUP) · Neoplasms
96. Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274.
    Galsky MD, Witjes JA, Gschwend JE, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 39393026 · NCT02632409 (CheckMate 274)
97. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
    Galsky MD, Daneshmand S, Izadmehr S, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 37783966 · NCT03451331
98. Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.
    Friedman CF, Manning-Geist BL, Zhou Q, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 38653864 · NCT03241745 · Endometrial Neoplasms
99. Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy.
    Friedberg JW, Bordoni R, Patel-Donnelly D, et al. · Blood · 2024 · Derived
    PubMed: PMID 37946283 · NCT01716806 · Hodgkin Disease
100. An LC-MS/MS method for determination of the bromodomain inhibitor ZEN-3694 and its metabolite ZEN-3791 in human plasma.
     Feng Y, Mahdi H, Piekarz R, et al. · Bioanalysis · 2024 · Derived
     PubMed: PMID 38497709 · NCT04840589 · Neoplasm Metastasis
101. Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer.
     Felip E, Metro G, Tan DSW, et al. · Lung Cancer · 2024 · Derived
     PubMed: PMID 38763104 · NCT02323126 · Carcinoma, Non-Small-Cell Lung
102. A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma.
     Enzler T, Nguyen A, Misleh J, et al. · Eur J Cancer · 2024 · Derived
     PubMed: PMID 38422585 · NCT04953962 · Pancreatic Neoplasms
103. Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.
     Elez E, Cubillo A, Alfonso PG, et al. · BMC Cancer · 2024 · Derived
     PubMed: PMID 38600471 · NCT03271047 · Neoplasms
104. Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.
     Ebrahimi H, Dizman N, Meza L, et al. · Nat Med · 2024 · Derived
     PubMed: PMID 38942995 · NCT05122546 · Carcinoma, Renal Cell
105. Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma.
     Duerinck J, Lescrauwaet L, Dirven I, et al. · Neuro Oncol · 2024 · Derived
     PubMed: PMID 39406392 · NCT03233152 (GlitIpNi) · Glioblastoma
106. Association between pathologic response and survival after neoadjuvant therapy in lung cancer.
     Deutsch JS, Cimino-Mathews A, Thompson E, et al. · Nat Med · 2024 · Derived
     PubMed: PMID 37903504 · NCT02998528 (CheckMate 816) · Carcinoma, Non-Small-Cell Lung
107. Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial.
     de Gooyer PGM, Verschoor YL, van den Dungen LDW, et al. · Nat Med · 2024 · Derived
     PubMed: PMID 39278994 · NCT03026140 (NICHE) · Colonic Neoplasms
108. FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial.
     Damato A, Bergamo F, Antonuzzo L, et al. · Front Oncol · 2024 · Derived
     PubMed: PMID 34970487 · NCT04072198 (NIVACOR) · Colorectal Neoplasms
109. Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis.
     D'Alessio A, Stefanini B, Blanter J, et al. · Lancet Oncol · 2024 · Derived
     PubMed: PMID 39437804 · NCT03510871 · Carcinoma, Hepatocellular
110. Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort.
     Corbaux P, Freyer G, Glehen O, et al. · Clin Cancer Res · 2024 · Derived
     PubMed: PMID 38819408 · NCT03959761 (ICONIC) · Ovarian Neoplasms
111. VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial.
     Coffman-D'Annibale K, Myojin Y, Monge C, et al. · J Immunother Cancer · 2024 · Derived
     PubMed: PMID 38184304 · NCT04166383 · Colorectal Neoplasms
112. Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.
     Choueiri TK, Albiges L, Barthélémy P, et al. · Lancet · 2024 · Derived
     PubMed: PMID 39284329 · NCT04987203 · Carcinoma, Renal Cell
113. Epithelium/imcDC2 axis facilitates the resistance of neoadjuvant anti-PD-1 in human NSCLC.
     Chen Y, Shao Z, Hao Z, et al. · J Immunother Cancer · 2024 · Derived
     PubMed: PMID 39134346 · NCT03732664
114. Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies.
     Chang JY, Xu X, Shroff GS, et al. · J Immunother Cancer · 2024 · Derived
     PubMed: PMID 39384194 · NCT04021043 · Neoplasm Metastasis
115. Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.
     Chalabi M, Verschoor YL, Tan PB, et al. · N Engl J Med · 2024 · Derived
     PubMed: PMID 38838311 · NCT03026140 (NICHE) · Colonic Neoplasms
116. Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors.
     Chae YK, Othus M, Patel S, et al. · J Immunother Cancer · 2024 · Derived
     PubMed: PMID 39343510 · NCT02834013 · Carcinoma, Transitional Cell
117. Neoadjuvant Treatment of Mismatch Repair-Deficient Colon Cancer - Clinically Meaningful?
     Cercek A · N Engl J Med · 2024 · Derived
     PubMed: PMID 38838316 · NCT03026140 (NICHE) · Colonic Neoplasms
118. The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214.
     Cella D, Choueiri TK, Hamilton M, et al. · Oncologist · 2024 · Derived
     PubMed: PMID 38280218 · NCT02231749 · Carcinoma, Renal Cell
119. Perioperative Nivolumab in Resectable Lung Cancer.
     Cascone T, Awad MM, Spicer JD, et al. · N Engl J Med · 2024 · Derived
     PubMed: PMID 38749033 · NCT04025879 · Carcinoma, Non-Small-Cell Lung
120. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
     Cannon TL, Rothe M, Mangat PK, et al. · J Clin Oncol · 2024 · Derived
     PubMed: PMID 38748939 · NCT02693535 (TAPUR) · Neoplasms
121. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
     Calfa CJ, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2024 · Derived
     PubMed: PMID 38354330 · NCT02693535 (TAPUR) · Neoplasms
122. Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial.
     Botsen D, Chabaud S, Perrier H, et al. · Dig Liver Dis · 2024 · Derived
     PubMed: PMID 38762353 · NCT05476796 (LOGICAN) · Neoplasm Metastasis
123. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
     Blank CU, Lucas MW, Scolyer RA, et al. · N Engl J Med · 2024 · Derived
     PubMed: PMID 38828984 · NCT04949113 (NADINA) · Melanoma
124. Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma.
     Bitar R, Salem R, Finn R, et al. · Radiology · 2024 · Derived
     PubMed: PMID 39560477 · NCT02576509 · Carcinoma, Hepatocellular
125. Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer.
     Barrera C, Corredor G, Viswanathan VS, et al. · NPJ Precis Oncol · 2024 · Derived
     PubMed: PMID 37264091 · NCT01673867 (CheckMate057)
126. Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial.
     Baretti M, Danilova L, Durham JN, et al. · Nat Commun · 2024 · Derived
     PubMed: PMID 39532835 · NCT03250273 · Neoplasm Metastasis
127. Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study.
     Awad MM, Le Bruchec Y, Lu B, et al. · Front Oncol · 2024 · Derived
     PubMed: PMID 34552864 · NCT02635061 · Carcinoma, Non-Small-Cell Lung
128. Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma.
     Ascierto PA, Mandalà M, Ferrucci PF, et al. · NEJM Evid · 2024 · Derived
     PubMed: PMID 39315864 · NCT02631447 (SECOMBIT) · Melanoma
129. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.
     Ascierto PA, Casula M, Bulgarelli J, et al. · Nat Commun · 2024 · Derived
     PubMed: PMID 38167503 · NCT02631447 (SECOMBIT) · Melanoma
130. ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-guided Analysis.
     Arrieta VA, Duerinck J, Burdett KB, et al. · Clin Cancer Res · 2024 · Derived
     PubMed: PMID 37939133 · NCT03233152 (GlitIpNi) · Glioblastoma
131. Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.
     Apolo AB, Girardi DM, Niglio SA, et al. · J Clin Oncol · 2024 · Derived
     PubMed: PMID 38954785 · NCT02496208 · Carcinoma, Renal Cell
132. Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.
     Andre T, Elez E, Van Cutsem E, et al. · N Engl J Med · 2024 · Derived
     PubMed: PMID 39602630 · NCT04008030 (CheckMate 8HW) · Colorectal Neoplasms
133. High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC.
     Altan M, Li R, Li Z, et al. · J Immunother Cancer · 2024 · Derived
     PubMed: PMID 39721752 · NCT03391869 · Carcinoma, Non-Small-Cell Lung
134. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study.
     Allaf ME, Kim SE, Master V, et al. · Lancet Oncol · 2024 · Derived
     PubMed: PMID 38942046 · NCT03055013 · Carcinoma, Renal Cell
135. Neoadjuvant therapy for oesophageal cancer: refining the armamentarium.
     Al-Batran SE, Koch C · Lancet · 2024 · Derived
     PubMed: PMID 38876135 · NCT05213312 · Esophageal Squamous Cell Carcinoma
136. Metabolic Reprogramming in Cancer: Implications for Immunosuppressive Microenvironment.
     Aden D, Sureka N, Zaheer S, et al. · Immunology · 2024 · Derived
     PubMed: PMID 39462179 · NCT02771626 · Melanoma
137. Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy.
     Wang C, Zeng Q, Gül ZM, et al. · Cell · 2024 · Background
     PubMed: PMID 38723627 · NCT07338981
138. Metabolic Dependencies in Pancreatic Cancer.
     Vaziri-Gohar A, Zarei M, Brody JR, et al. · Front Oncol · 2024 · Background
     PubMed: PMID 30631752 · NCT04787991 (REVOLUTION)
139. Evolving treatment paradigms in esophageal cancer.
     Turgeman I, Ben-Aharon I · Ann Transl Med · 2024 · Background
     PubMed: PMID 34164537 · NCT05213312 · Esophageal Squamous Cell Carcinoma
140. Association of Clostridium butyricum Therapy Using the Live Bacterial Product CBM588 with the Survival of Patients with Lung Cancer Receiving Chemoimmunotherapy Combinations.
     Tomita Y, Sakata S, Imamura K, et al. · Cancers (Basel) · 2024 · Background
     PubMed: PMID 38201474 · NCT06399419 · Carcinoma, Renal Cell
141. The biotherapeutic Clostridium butyricum MIYAIRI 588 strain potentiates enterotropism of Rorγt+Treg and PD-1 blockade efficacy.
     Paz Del Socorro T, Oka K, Boulard O, et al. · Gut Microbes · 2024 · Background
     PubMed: PMID 38385162 · NCT06399419 · Carcinoma, Renal Cell
142. Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis.
     Patel JS, Woo Y, Draper A, et al. · J Immunother Cancer · 2024 · Background
     PubMed: PMID 38531662 · NCT07338981
143. Enhanced therapeutic outcomes with atezolizumab-bevacizumab and SIRT combination compared to SIRT alone in unresectable HCC: A promising approach for improved survival.
     Mejait A, Roux C, Soret M, et al. · Clin Res Hepatol Gastroenterol · 2024 · Background
     PubMed: PMID 38191073 · NCT07482059
144. Why does circadian timing of administration matter for immune checkpoint inhibitors' efficacy?
     Karaboué A, Innominato PF, Wreglesworth NI, et al. · Br J Cancer · 2024 · Background
     PubMed: PMID 38834742 · NCT07338981
145. Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab.
     Herbreteau G, Langlais A, Greillier L, et al. · J Clin Med · 2024 · Background
     PubMed: PMID 33261056 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
146. Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade.
     Fortin BM, Pfeiffer SM, Insua-Rodríguez J, et al. · Nat Immunol · 2024 · Background
     PubMed: PMID 38806707 · NCT07338981
147. Neoadjuvant in Situ and Systemic Immunotherapy with Lymph Node Cryoablation in Resectable Stage III Melanoma Metastasis: a Proof-of-Concept Study.
     Braud A, Auloge P, Meyer N, et al. · Cardiovasc Intervent Radiol · 2024 · Background
     PubMed: PMID 38570342 · NCT03949153 (CRIRIN) · Melanoma